Agios Pharmaceuticals News

Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Yahoo FinanceMay 5 08:10 ET

Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow JonesMay 3 12:00 ET

Express News | Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $33

BenzingaMay 3 11:50 ET

Agios Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 -4.57% Goldman Sachs $29 → $33 Maintains Neutral 04/09/2024 — Cantor Fitzgerald Reiterates → O

BenzingaMay 3 11:49 ET

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 3 11:10 ET

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company

GlobeNewswireMay 3 07:00 ET

Earnings Call Summary | Agios Pharmaceuticals(AGIO.US) Q1 2024 Earnings Conference

The following is a summary of the Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript:Financial Performance:Agios Pharmaceuticals reported net Q1 2024 revenue of $8.2 million from its

moomoo AIMay 3 02:14 ET · Conference Call

Q1 2024 Agios Pharmaceuticals Inc Earnings Call

Yahoo FinanceMay 2 22:45 ET

Earnings Call: Agios Pharmaceuticals Outlines Robust Pipeline and Financial Health

InvestingMay 2 20:22 ET

Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 2 16:32 ET

Agios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss Than Expected With Strong Revenue ...

Yahoo FinanceMay 2 08:44 ET

Express News | Agios Pharmaceuticals' Cash, Cash Equivalents and Marketable Securities of $714.3M As Of March 31, 2024

BenzingaMay 2 07:06 ET

Agios Pharmaceuticals Q1 2024 GAAP EPS $(1.45) Beats $(1.64) Estimate, Sales $8.189M Miss $8.370M Estimate

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.45) per share which beat the analyst consensus estimate of $(1.64) by 11.59 percent. This is a 1.36 percent increase over losses of

BenzingaMay 2 07:06 ET

Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q1 Revenue $8.2M

07:00 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q1 Revenue $8.2M

MT NewswiresMay 2 07:00 ET

Express News | Agios Reports Business Highlights and First Quarter 2024 Financial Results

ReutersMay 2 07:00 ET

Agios Pharmaceuticals 1Q Loss/Shr $1.45 >AGIO

Agios Pharmaceuticals 1Q Loss/Shr $1.45 >AGIO

Dow JonesMay 2 07:00 ET

Agios Pharmaceuticals Q1 2024 Earnings Preview

Seeking AlphaMay 1 14:32 ET

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will

GlobeNewswireApr 18 07:00 ET

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares

Simply Wall StApr 14 08:00 ET

Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)

Yahoo FinanceApr 10 19:01 ET